The F, hybrids of the autoimmune New Zealand Black (NZB) mice and the phenotypically normal New Zealand White (NZW) mouse strain, develop severe systemic autoimmune disease, more fulminant than that found in the parental NZB strain . These mice manifest several immune abnormalities including antibodies to nuclear antigens and subsequent development of a fatal, immune complex-mediated glomerulonephritis with female predominance, remarkably similar to systemic lupus erythematosus (SLE) in humans.
AGE OF MICE (months)
Results FIGURE l . Survival of NZB/ W F, female mice treated with IFN-y. 25 NZB/W F, mice treated with IFN-y (0) are compared with 25 age-and sex-matched NZB/W F, animals given PBS (0) and to 16 NZW parental strain treated with IFN-y (A) . Arrows indicate the time period of treatment.
Monoclonal Antibodies . DB-1 is an IgGI mouse anti-rat IFN-y mAb that exhibits highaffinity binding for rat and mouse IFN-y and efficiently neutralizes the antiviral activity of both animal interferon species (6) . TE33 is an IgGI mouse mAb specific to residues 50-64 of cholera toxin B subunit, and was used as a control antibody .
DB-1 monoclonal anti IFN-y antibodies were purified from ascites fluid of BALB/c mice injected with 5 x 106 DB-1 hybridoma cells . Antibodies were purified by 45% ammonium sulfate precipitation (twice) followed by chromatography on DEAE-Sephacel column . The ability of DB-I to inhibit IFN-y-induced Ia expression was assayed in vitro on the murine myelomonocytic cell line WEHI-3 . Treatment of these cells with murine IFN-y for 24-48 h induces the expression of la antigens on their surface (7) . Treatment of WEHI-3 cells with 10 U/ml of murine IFN-y in the presence of DB-1 at 0.5 mg/ml caused inhibition of^-70% of la expression as detected with fluorescein-conjugated MK-D6 (anti-la') mAb on a FACS IV (Becton Dickinson & Co., Mountain View, CA).
Measurement of Anti-DNA Antibodies. Anti-DNA-specific antibodies in sera were assayed by an ELISA as described (8) .
Proteinuria . Proteinuria was measured colorimetrically by the use of Uristix (Miles Laboratories Inc ., Elkhart, IN) .
Two groups of 25 female NZB/W F, mice, 4 mo old, received rIFN-y or equivalent volumes of PBS over a period of 3 mo. As an additional control group, 16 age-and sex-matched mice of the parental strain NZW, were similarly treated with IFN--y . Death occurred at an earlier age in the NZB/W F, group that received IFN-y compared with the PBS control mice (Fig. 1) . The difference in survival between treated and control mice was statistically significant (p <_ 0.001) .
While PBS-treated NZB/W F, control mice began to die at -8 mo of age (50% survival, 9.5 mo), in the IFN-1-treated group 75-80% of NZB/W F, were dead by 8 mo . The life span of the NZW control group was not affected by the IFNy treatment . High grade proteinuria was detected significantly earlier in the IFN-y-treated NZB/W F, group compared with the control group ( Fig. 2A) . The onset of death correlated closely with the onset and amount of proteinuria . Similarly, anti-DNA antibodies reached peak levels earlier in the IFN-y treatedgroup than in the control group (Fig. 2B) , although no significant differences in the peak levels of anti-DNA antibodies were observed between the two groups as a whole .
In a separate experiment, treatment with IFN-y was initiated at different ages . Since no significant differences were found between PBS-versus nonrelevant antibody-treated animals, they are presented together as a single control group. To reflect more accurately thedevelopment of renal disease in all mice (alive and dead), a correction factor was induced. Thus, each point reflects the current level of proteinuria as well as the last measurement of proteinuria in deceased mice . (B) Effect of the various treatments on the appearance of anti-DNA antibodies . The open bars represent the mean age at which anti-DNA antibodies were detected in the various groups, while dashed bars represent the mean age ± SD at which peak levels of anti-DNA antibody occurred . Note that at the age when anti-DNA antibody was detected, the difference between the PBS-and the IFNy-treated groups is not significant, while the difference between PBS-and DB-1-treated groups is significant (p <-0.05) . The differences in age at peak levels between PBStreated versus IFN-y-or DB-1-treated groups are significant (p < 0.005 and p :-0.0005, respectively) . between 2.5 and 6 .5 mo, using the same treatment protocol . Treatment starting at various ages between 2 .5 and 6 mo resulted in significantly earlier appearance of high grade proteinuria and accelerated mortality when compared with agematched control groups . When IFN-y treatment started at 6 .5 mo, no significant difference in lifespan was observed between treated and controls (not shown) .
Given these results we asked whether we could block disease development by using mAb to IFN-y. Two groups of 20 female NZB/W F, mice received purified anti-IFN-y mAb (DB-1), and as controls, 10 mice received an irrelevant monoclonal IgGI antibody (TE33) and 20 animals received PBS . All mice were 4 mo old at the beginning of the experiment. One group was treated with 2 mg DB-1 intraperitoneally three times per week and the other received 2 mg DB-1 once a week. Treatment was given for a period of 3 mo. Fig. 3 shows the improved survival rate of mice treated with DB-1 . At the age of 11 mo, 80-85% of both control groups were dead, while 95% of mice were alive in both DB-1-treated groups. No difference was found between mice given weekly 2-mg injections of anti-IFN-y compared with those receiving 2 mg antibody three times per week. In parallel with the dramatic prolonged survival of DB-1-treated mice, the development of severe proteinuria was significantly delayed (Fig. 2A) . By 9 mo >60% in each control group had high grade proteinuria, but none of the mice treated with DB-1 had proteinuria of this degree. At the age of 11 mo^-30-40% of treated animals showed severe proteinuria . The titer of anti-DNA antibody reached maximal levels at 7-8 mo in the control groups, while DB-1-treated animals showed similar levels at^-10 mo of age (Fig. 2B) . It is noteworthy that the PBS control group and the irrelevant antibody control groups are very similar in terms of survival, proteinuria, and anti-DNA antibody profiles.
Discussion During the past decade many diverse activities have been attributed to IFN-7. Despite the ability of IFN-,y to mediate such a variety of functions, and to exert remarkably pleomorphic effects on the immune system (9), surprisingly little is known about the biological relevance of IFN-, y to the homeostasis of the immune system in vivo .
Two lines of experimental observations led us to undertake these experiments. First, IFN-y has been established as the prototype lymphokine to induce enhancement of synthesis and surface expression of MHC class II antigens in a wide variety of cell types both in vitro and in vivo (10, 11) . Inappropriate expression of MHC class II molecules has been shown in several autoimmune processes both in animal models (12) and human diseases (13). Moreover, it seems possible that the induction of MHC molecules is due to release of IFN-,y by activated T cells. Thus, rat astrocytes induced in vitro to express la molecules by IFN-7 were able to present myelin basic protein to encephalitogenic T cell lines in a MHCrestricted manner (14) . Second, studies in this laboratory have demonstrated that in vivo administration of mAbs specific for an Ia region gene product (I-A°) induced remission in NZB/W F, mice with moderate renal disease (15) . Anti-la mAb therapy was effective in several other autoimmune disease models such as experimental allergic encephalitis, experimentally induced myasthenia gravis, and in spontaneous autoimmune diabetes and thyroiditis in BB/W rats.
Our results clearly suggest that IFN-,y might have a major biological role in aberrant immune regulation causing the development of murine lupus nephritis.
The fact that administration of IFN-7 accelerated the development of the nephritis does not by itself prove that this lymphokine has a major role in the development of the disease, since other lymphokines and cellular factors share some activities with IFN-y : thus, for example, in addition to IFN-y, class II MHC expression has been enhanced by IFN-« or -S (16) and IL-4 (BSF-1) (17) . Therefore, the blocking of IFN-y might have no effect on other possible regulatory factors and thus have no effect on the progression of the disease . On the other hand, if antibody to IFN-7 is able to block or delay progression of disease, this would argue in favor of IFN-, y playing a principal role in the pathogenesis of the disease. Thus, the experiments with monoclonal anti-IFN-y were essential to confirm this point.
Whether the results of this study are applicable in a more general sense to the initiation and propagation of other autoimmune processes, or even during normal ongoing immune responses, remains an open question at the present time . Similarly the mechanism of IFN-y activity in this in vivo system remains to be determined . While we favor the hypothesis that IFN-y activates the immune system by upregulating class II MHC antigen expression as initially proposed by Bottazzo et al . (18) , it must be noted that IFN-y has both activating and inhibiting effects on B cell differentiation and B cell responses, and at least some of the autoimmune abnormalities in NZB/W F, mice may be attributed to B cell effects (19) . Alternatively, it is possible that IFN-y has an indispensable physiological function that is entirely distinct from any yet defined.
In considering potential therapeutic applications of IFN-'r (20), our observations indicate that this lymphokine should not be considered exempt from possible untoward consequences . The present study, coupled with other observations (21) , suggests that IFN-y may be contraindicated in patients with certain autoimmune diseases .
Conversely, we have shown that in vivo therapy with monoclonal anti-IFN-y can significantly alter the course of murine lupus-like nephritis. This may have implications for the treatment of SLE in man.
Summary
The (NZB X NZW)F, mouse is recognized as an important animal model of the human disease systemic lupus erythematosus (SLE). Groups of NZB/W F, mice were treated either with IFN-y or with PBS. The results demonstrate that IFN-treated animals have accelerated development of fatal immune complex glomerulonephritis relative to age-matched controls . On the other hand, administration of mAbs specific for IFN-y to such mice from 4 to 7 mo of age resulted in significant remission. Development of both proteinuria and anti-DNA antibodies were delayed and survival at 11 mo was increased from <20% to 95% in treated mice relative to controls (p <_ 0.001). These findings may have therapeutic implications for the treatment of SLE.
